Other SSAO inhibitor Programs

Pharmaxis is currently investigating an additional opportunities in its SSAO inhibitor program:

AQ05646

SSAO/MPO – respiratory and cardiovascular

SSAO/VAP-1 is upregulated in models of inflammatory lung diseases such as cystic fibrosis and chronic obstructive pulmonary disease and COPD patients also have increased SSAO/VAP-1 in the lung. Pharmaxis has developed SSAO inhibitors that are effective in pre clinical models and has the potential to enhance efficacy through enhanced chemistry to target the additional myloperoxidase (MPO) pathway.